Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ramucirumab - Eli Lilly and Company

Drug Profile

Ramucirumab - Eli Lilly and Company

Alternative Names: Anti-flk-1 monoclonal antibody - ImClone; Anti-KDR monoclonal antibody - ImClone; Anti-VEGFR 2 monoclonal antibody - ImClone; Cyramza; IMC-1121; IMC-1121-B; IMC-1C11 - ImClone; LY-3009806; Ramcilumab; ramsilmab; Ramsilomab; Ramsylmab; Ramsylumab; Sairamza; Silamza

Latest Information Update: 14 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dyax
  • Developer AstraZeneca; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer; Non-small cell lung cancer
  • Registered Liver cancer
  • Phase III Oesophageal cancer; Urogenital cancer
  • Phase II Biliary cancer; Carcinoid tumour; Solid tumours; Synovial sarcoma
  • Phase I/II Head and neck cancer; Pancreatic cancer
  • No development reported Breast cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 07 Oct 2019 Efficacy and adverse events data from the phase III RELAY trial in Non-small cell lung cancer released by Eli Lilly and Company
  • 27 Jun 2019 The CHMP of EMA adopts a positive opinion and recommends change in marketing authorisation of ramucirumab in Liver cancer (to include treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib)
  • 18 Jun 2019 Eli Lilly and Company plans a phase II trial for Synovial Sarcoma in Australia, Belgium, France, Germany, Italy, Japan, Netherlands, Spain, United Kingdom and USA (EudraCT2018-004243-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top